Ask AI
Sara A. Hurvitz

Sara A. Hurvitz, MD, FACP

Professor of Medicine

Division of Hematology-Oncology

David Geffen School of Medicine at UCLA

Los Angeles, California, United States of America

Professor of Medicine
Smith Family Endowed Chair in Women’s Health
Senior Vice President, Clinical Research Division
Fred Hutchinson Cancer Center
Head, Division of Hematology and Oncology
Department of Medicine, UW Medicine
Seattle, Washington

Explore Activities by Sara A. Hurvitz

Title
Format
Credit Type
Credits
Changing the Paradigm in HER2-Positive Early Breast Cancer

Content Format:

Podcast

Credit Type:

--

Credits:

--
FAQs With Expert Perspectives on HER2-Directed ADCs in Breast Cancer: Treatment Selection, Sequencing, and Patient-Centered Care

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
Integrating HER2-Directed ADCs Across Early and Metastatic Breast Cancer: Practical Strategies for Testing, Sequencing, and Patient-Centered Care

Content Format:

Video

Credit Type:

AAPA | ABIM MOC | ACPE | AMA | ANCC

Credits:

1.50
Integrating HER2-Directed ADCs Across Early and Metastatic Breast Cancer: Practical Strategies for Testing, Sequencing, and Patient-Centered Care

Content Format:

Slideset

Credit Type:

--

Credits:

--
ClinicalThought Expert Office Hours Forum: Integrating HER2-Directed ADCs Across Early and Metastatic Breast Cancer: Practical Strategies for Testing, Sequencing, and Patient-Centered Care

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
Role of the Multidisciplinary Team in Achieving Comprehensive and Individualized Care of Patients with HR-positive/HER2-negative Metastatic Breast Cancer and Preexisting Comorbidities

Content Format:

Podcast

Credit Type:

--

Credits:

--
Evolving Standards in HR+/HER2- Metastatic Breast Cancer: Optimizing Outcomes Through Precision Medicine and Real-world Insight

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
Optimizing Treatment for Patients With HR-Positive/HER2-Negative MBC

Content Format:

Text Module

Credit Type:

AMA

Credits:

0.50
Optimizing Treatment for Patients With HR-Positive/HER2-Negative MBC

Content Format:

Slideset

Credit Type:

--

Credits:

--
Treating the Whole Patient: Understanding Needs of Patients With HR-Positive/HER2-Negative MBC and Comorbidities

Content Format:

Text Module

Credit Type:

AMA

Credits:

0.50
Treating the Whole Patient: Understanding Needs of Patients With HR+/HER2- MBC and Comorbidities

Content Format:

Slideset

Credit Type:

--

Credits:

--
Los expertos responden a sus preguntas sobre los inhibidores de CDK4/6 en el cáncer de mama RH+/HER2-

Content Format:

PDF

Credit Type:

--

Credits:

--
Conversaciones sobre el cáncer de mama RH positivo/HER2 negativo en el panorama terapéutico en expansión de los inhibidores de CDK4/6

Content Format:

PDF

Credit Type:

--

Credits:

--
Especialistas respondem às suas perguntas sobre inibidores de CDK4/6 no câncer de mama HR+/HER2-

Content Format:

PDF

Credit Type:

--

Credits:

--
Conversas sobre o câncer: o cenário terapêutico em expansão para inibidores de CDK4/6 em câncer de mama HR-positivo/HER2-negativo

Content Format:

PDF

Credit Type:

--

Credits:

--
Key Studies in Breast Cancer: Independent Conference Coverage of the 2024 ASCO Annual Meeting

Content Format:

Text Module

Credit Type:

AMA

Credits:

0.75
Des experts répondent à vos questions concernant les inhibiteurs de CDK4/6 dans le cancer du sein HR+/HER2-

Content Format:

PDF

Credit Type:

--

Credits:

--
Conversations autour du cancer portant sur l'élargissement du paysage thérapeutique des inhibiteurs de CDK4/6 dans le traitement du cancer du sein HR+/HER2-

Content Format:

PDF

Credit Type:

--

Credits:

--
Experts Discuss the Role of CDK4/6 Inhibitors in HR+/HER2- Breast Cancer

Content Format:

Podcast

Credit Type:

ABIM MOC | AMA

Credits:

0.50
Experts Answer Your Questions on CDK4/6 Inhibitors in HR+/HER2- Breast Cancer

Content Format:

Clinical Thought

Credit Type:

ABIM MOC | AMA

Credits:

0.25
Cancer Conversations on the Expanding Therapeutic Landscape for CDK4/6 Inhibitors in HR-Positive/HER2-Negative Breast Cancer

Content Format:

Video

Credit Type:

ABIM MOC | AMA

Credits:

1.50
Cancer Conversations on the Expanding Therapeutic Landscape for CDK4/6 Inhibitors in HR-Positive/HER2-Negative Breast Cancer

Content Format:

Slideset

Credit Type:

ABIM MOC | AMA

Credits:

1.00
An Expert’s Guide to ASCO 2024: Preview of the Top Abstracts

Content Format:

Conference Coverage

Credit Type:

--

Credits:

--
Highlights From the 2023 San Antonio Breast Cancer Symposium

Content Format:

Text Module

Credit Type:

AAPA | ACPE | AMA | ANCC

Credits:

1.25
An Expert’s Guide to SABCS 2023: A Preview of the Top Abstracts

Content Format:

Conference Coverage

Credit Type:

--

Credits:

--
FAQs: The Expanding Role of Antibody–Drug Conjugates in Breast Cancer

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
Optimizing Integration of Precision Therapy Into the Treatment of HER2-Low, HR-Positive, and Triple Negative Breast Cancer: A Focus on HER2 Targeted and TROP-2–Targeted Therapy

Content Format:

Video

Credit Type:

AMA

Credits:

1.50
Practical Adverse Event Management for Optimal Therapeutic Outcomes

Content Format:

Slideset

Credit Type:

--

Credits:

--
Advances in Metastatic Breast Cancer Care: Guidance on Antibody–Drug Conjugate Therapy for the Community Multidisciplinary Team

Content Format:

Slideset

Credit Type:

--

Credits:

--